A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionSofosbuvir/velpatasvir: A promising combinationClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CHepatitis C treatment: where are we now?Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionDirect-acting antivirals for chronic hepatitis C.Hepatitis C Virus Infection in Chronic Kidney Disease.Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.Direct-acting antivirals for chronic hepatitis C
P2860
Q26746563-FAE95400-C253-4142-A7F4-0560F862CB12Q27468954-E9B3CD02-C63E-403C-AFB0-0A603A822373Q28080225-4103B773-1B94-4C11-A9BD-752318600682Q30378509-FD764111-4741-43A1-B2E3-336D55014D64Q34506788-BF4860BC-8F20-4CF4-98D4-AC6045EAF5A3Q34557595-EA23855F-45BC-48E3-B6AB-A8083E9397CDQ38812607-28E1CE4F-89FF-484E-BA39-2D1A833F45AFQ38949900-8CA697A8-7DA1-4ED8-B627-3BAACBD45027Q38976791-D5E75E69-46E7-4828-9803-ED8A14545A4EQ39090420-F8C9F548-5FB3-4D83-B711-B0EAA2245706Q40334467-E9BD1980-B768-46CA-8457-FAF450904641Q40337619-7441BCDF-D415-47F2-BD1B-BCB966808CC1Q40677674-E20269CE-7E99-47A8-8FF9-1E83586F9637Q52326653-4E4CC099-A84D-48E8-B669-F8C0A21AD9DAQ57389418-3B06C54B-B9AB-4975-98B9-4535F8579E8C
P2860
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 1, randomized, dose-ra ...... enotype 1-4 hepatitis C virus.
@en
type
label
A phase 1, randomized, dose-ra ...... enotype 1-4 hepatitis C virus.
@en
prefLabel
A phase 1, randomized, dose-ra ...... enotype 1-4 hepatitis C virus.
@en
P2093
P2860
P356
P1476
A phase 1, randomized, dose-ra ...... enotype 1-4 hepatitis C virus.
@en
P2093
B Freilich
D M Brainard
M Rodriguez-Torres
P2860
P304
P356
10.1111/JVH.12435
P577
2015-07-16T00:00:00Z